EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease

Pauline Wils, Vipul Jairath, Bruce E Sands, Fernando Magro, Walter Reinisch, David Rubin iD, Silvio Danese, Cédric Baumann, Laurent Peyrin-Biroulet iD

United European Gastroenterology Journal · 2023

DOI: 10.1002/ueg2.12455 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Pauline Wils und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The accumulation of multiple randomized controlled trials in the field of inflammatory bowel diseases provides an opportunity to compare treatment effects between phase 2 and 3 trials. We aimed to determine whether treatment effects observed in phase 3 investigating biologics and small molecule drugs differed from those in their preceding phase 2 trial.

Methods

We first performed a review of phase 2 and phase 3 trials enrolling ulcerative colitis (UC) or Crohn's disease (CD) patients. We compared the percent overall success for key endpoints between phases (several phase 3 could be matched to a single phase 2 trial). Then, we compared the percent overall success in the matched phase 2 and 3 trials (ratio 1:1), and performed sensitivity analysis.

Results

We identified 14 phase 2 (8 CD; 6 UC) and 24 phase 3 (13 CD; 11 UC) trials. In CD, the different analyses suggest that the percentage of overall success of clinical remission and clinical response was significantly higher in phase 2 than in phase 3 trials. In UC, the analyses suggest collectively that the percent of treatment effect seemed similar for clinical remission, clinical response and histologic outcomes between phases but with a lower percentage of overall success in phase 2 than in phase 3 trials for endoscopic endpoints.

Conclusions

In UC, we observed a similar percentage of treatment effect for clinical and histologic outcomes between phase 2 and 3 trials but not for endoscopic outcomes. Whereas in CD, we showed a failure to reproduce similar results between phases. These results may help sponsors in the design of future drug development programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesColitis, UlcerativeCrohn DiseaseBiological ProductsHumansEndoscopyClinical Trials, Phase III as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Crohn's diseasebiologicsinflammatory bowel diseaserandomized controlled trialulcerative colitis

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France.
  • Inserm, CHU Lille, U1286- INFINITE- Institute for Translational Research in Inflammation, University of Lille, Lille, France.
  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
  • The Dr Henry J Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal.
  • Division Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: David Rubin, Laurent Peyrin-Biroulet

Zitieren

APA

Wils, P., Jairath, V., Sands, B. E., Magro, F., Reinisch, W., Rubin, D., Danese, S., Baumann, C., & Peyrin-Biroulet, L. (2023). Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12455

Vancouver

Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, et al. Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12455

BibTeX
@article{Wils2023,
  author = {Wils, Pauline and Jairath, Vipul and Sands, Bruce E and Magro, Fernando and Reinisch, Walter and Rubin, David and Danese, Silvio and Baumann, Cédric and Peyrin-Biroulet, Laurent},
  title = {Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease},
  journal = {United European Gastroenterology Journal},
  year = {2023},
  doi = {10.1002/ueg2.12455}
}
Kostenlos starten →